MARKET

VOR

VOR

Vor Biopharma Inc.
NASDAQ
2.210
+0.050
+2.31%
Closed 18:38 03/27 EDT
OPEN
2.190
PREV CLOSE
2.160
HIGH
2.230
LOW
2.120
VOLUME
224.67K
TURNOVER
0
52 WEEK HIGH
6.17
52 WEEK LOW
1.620
MARKET CAP
150.65M
P/E (TTM)
-1.2599
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Inotiv (NOTV) and Vericel (VCEL)
TipRanks · 2d ago
Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)
TipRanks · 2d ago
Weekly Report: what happened at VOR last week (0318-0322)?
Weekly Report · 3d ago
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
3 analysts have recently maintained Buy ratings on Immatics, Vor Biopharma and Jazz Pharmaceuticals. The 3 stocks are in the Healthcare sector and are expected to make moves following their insider activities. 3 analysts just weighed in on  Immatics (IMTX – Research Report), Vor Bipharma (VOR – Research report) and Jazz pharmaceuticals with bullish sentiments.
TipRanks · 3d ago
MASI, PLRX and CGC are among after hour movers
On the Move MASI, PLRX and CGC are among after hour movers. Airship AI Holdings and AISP are among the losers in the tech sector. The day's top 10 stocks include CAMP, CGNX and MLCO.
Seeking Alpha · 5d ago
Vor Biopharma Price Target Maintained With a $12.00/Share by JMP Securities
Dow Jones · 5d ago
JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)
TipRanks · 6d ago
More
About VOR
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Webull offers Vor Biopharma Inc stock information, including NASDAQ: VOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VOR stock methods without spending real money on the virtual paper trading platform.